Multi-arm multi-stage survival trial design with arm-specific stopping rule

Area of Science:

• Biostatistics
• Clinical Trial Design
• Survival Analysis

Background:

• Traditional two-arm randomized trials are inefficient for evaluating multiple treatments.
• Multi-arm multi-stage (MAMS) designs allow simultaneous evaluation but can reduce the probability of selecting the best arm if stopped prematurely.
• Resource limitations and the need to test numerous interventions necessitate more efficient trial designs.

Purpose of the Study:

• To develop an improved multi-arm multi-stage (MAMS) survival trial design.
• To enhance the selection probability of the most effective treatment arm.
• To control the familywise type I error rate in clinical trials with multiple treatment arms.

Main Methods:

• Development of a group sequential MAMS survival trial design.
• Incorporation of an arm-specific stopping rule for early efficacy success.
• Statistical methods to control the familywise type I error in a strong sense.

Main Results:

• The proposed design effectively controls the familywise type I error.
• The method significantly increases the probability of selecting the truly best treatment arm.
• The design offers a more efficient approach to evaluating multiple survival interventions.

Conclusions:

• The novel group sequential MAMS survival design with arm-specific stopping rules is a statistically robust and efficient method.
• This approach optimizes the identification of superior treatments in clinical trials.
• The design provides a valuable tool for researchers facing challenges with multiple experimental treatments and limited resources.